Detail (Long)
<b>Palivizumab-eligible infants <8 mo:</b> Follow AAP recommendations for <a href=https://online.epocrates.com/e/deeplink/drugs/10a2278/Synagis><u><b>palivizumab (Synagis)</b></u></a> ppx when appropriate nirsevimab dose isn’t available.<sup>1,2</sup><br>
◦ <b>Palivizumab ppx is recommended for:</b> infants born before 29 wk gestation; preterm infants w/ chronic lung dz of prematurity (birth at <32 wk gestation and requiring >21% O<sub>2</sub> for ≥28 days after birth); certain infants w/ hemodynamically significant heart dz.<br>
◦ Palivizumab ppx is <b>not recommended</b> for: otherwise healthy infants born at or after 29 wk gestation; prevention of health care–associated RSV dz.<br>
◦ <b>Dosing.</b> Clinicians may administer up to 5 monthly doses of palivizumab (15 mg/kg per dose) during the RSV season. Qualifying infants born during the RSV season may require fewer doses—e.g., those born in Jan. would receive their last dose in Mar.<br>
◦ <b>D/c monthly ppx in any child who experiences a breakthrough RSV hospitalization.</b><br>
◦ <b>Alaska Native and possibly selected other American Indian populations:</b> RSV dz burden and costs associated w/ transport from remote locations may result in broader use of palivizumab for RSV prevention.<br>
◦ <b>For a related resource, see also</b> <a href=https://www.epocrates.com/e/guideline/12_24-0><u>Bronchiolitis Prophylaxis With Palivizumab in Children: 2014 AAP Guideline/Policy Statement | epocrates Guideline Synopsis</u></a>
◦ <b>Palivizumab ppx is recommended for:</b> infants born before 29 wk gestation; preterm infants w/ chronic lung dz of prematurity (birth at <32 wk gestation and requiring >21% O<sub>2</sub> for ≥28 days after birth); certain infants w/ hemodynamically significant heart dz.<br>
◦ Palivizumab ppx is <b>not recommended</b> for: otherwise healthy infants born at or after 29 wk gestation; prevention of health care–associated RSV dz.<br>
◦ <b>Dosing.</b> Clinicians may administer up to 5 monthly doses of palivizumab (15 mg/kg per dose) during the RSV season. Qualifying infants born during the RSV season may require fewer doses—e.g., those born in Jan. would receive their last dose in Mar.<br>
◦ <b>D/c monthly ppx in any child who experiences a breakthrough RSV hospitalization.</b><br>
◦ <b>Alaska Native and possibly selected other American Indian populations:</b> RSV dz burden and costs associated w/ transport from remote locations may result in broader use of palivizumab for RSV prevention.<br>
◦ <b>For a related resource, see also</b> <a href=https://www.epocrates.com/e/guideline/12_24-0><u>Bronchiolitis Prophylaxis With Palivizumab in Children: 2014 AAP Guideline/Policy Statement | epocrates Guideline Synopsis</u></a>